前列腺癌永久性近距离放疗后空间剂量-体积关系与性功能下降分析
该研究纳入115例接受Pd-103近距离放疗的cT1-T2期前列腺癌患者,分析前列腺周围解剖结构剂量与勃起功能障碍(ED)结局的关系。回归树分析将患者分为低、中、高ED风险组(2年平均SHIM分别为20.03、15.02、5.54)。对于基线功能良好(SHIM≥17)的患者,前列腺尾侧亚尖区(SAR)1 cm外扩条件下20%体积接受≥72.75 Gy的剂量最能预测2年勃起功能结局。
要点
- 前列腺尾侧亚尖区(SAR)剂量是预测勃起功能结局的唯一显著区域。
- 基线SHIM≥17者,SAR 1 cm外扩下20%体积剂量≥72.75 Gy最能预测2年勃起功能。
- 回归树风险分组在多变量分析中仍显著预测勃起功能结局。
核心结论
- 前列腺尾侧亚尖区(SAR)剂量可预测基线功能良好患者的勃起功能结局,最小化该区域剂量或可改善近距离放疗后勃起功能。
研究设计与样本
- 机构队列研究,纳入10年间接受Pd-103近距离放疗的cT1-T2期前列腺癌患者115例,均有2年完整随访。
- 使用男性性健康量表(SHIM)评估性功能,计算区域危及器官和前列腺周围区域的剂量体积直方图(含和不含外扩以考虑勾画不确定性),采用回归树分析对患者进行ED风险分组。
主要发现
- 单因素分析中,前列腺尾侧亚尖区(SAR)是唯一剂量体积直方图参数对勃起功能结局显著的定义区域。
- 回归树分析将患者分为低ED风险组(2年平均SHIM 20.03)、中ED风险组(15.02)和高ED风险组(5.54)。
- 基线功能良好(SHIM≥17)患者中,SAR 1 cm外扩条件下20%体积接受≥72.75 Gy的剂量最能预测2年勃起功能结局。
- 多因素分析中,回归树风险分组在调整基线SHIM和年龄后仍显著预测勃起功能结局。
关键数值与推荐
- 基线SHIM≥17患者中,SAR 1 cm外扩条件下20%体积剂量≥72.75 Gy最能预测2年勃起功能结局。
- 回归树分组:低ED风险组2年平均SHIM 20.03,中ED风险组15.02,高ED风险组5.54。
临床怎么用
- 作者认为,最小化前列腺尾侧亚尖区(SAR)剂量或可改善前列腺近距离放疗后的勃起功能结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To explore relationships between dose to periprostatic anatomic structures and erectile dysfunction (ED) outcomes in an institutional cohort treated with prostate brachytherapy. METHODS: The Sexual Health Inventory for Men (SHIM) instrument was administered for stage cT1-T2 prostate cancer patients treated with Pd-103 brachytherapy over a 10-year interval. Dose volume histograms for regional organs at risk and periprostatic regions were calculated with and without expansions to account for contouring uncertainty. Regression tree analysis clustered patients into ED risk groups. RESULTS: We identified 115 men treated with definitive prostate brachytherapy who had 2 years of complete follow-up. On univariate analysis, the subapical region (SAR) caudal to prostate was the only defined region with dose volume histograms parameters significant for potency outcomes. Regression tree analysis separated patients into low ED risk (mean 2-year SHIM 20.03), medium ED risk (15.02), and high ED risk (5.54) groups. Among patients with good baseline function (SHIM ≥ 17), a dose ≥72.75 Gy to 20% of the SAR with 1 cm expansion was most predictive for 2-year potency outcome. On multivariate analysis, regression tree risk group remained significant for predicting potency outcomes even after adjustment for baseline SHIM and age. CONCLUSION: Dose to the SAR immediately caudal to prostate was predictive for potency outcomes in patients with good baseline function. Minimization of dose to this region may improve potency outcomes following prostate brachytherapy.
引用
- Peng LC, Mian OY, Lakshminarayanan P, et al. Analysis of Spatial Dose-Volume Relationships and Decline in Sexual Function Following Permanent Brachytherapy for Prostate Cancer. Urology. 2019. PMID: 31454660. doi:10.1016/j.urology.2019.08.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。